Niagen Bioscience, Inc. 8-K

What Happened
Niagen Bioscience, Inc. (NAGE) filed an 8‑K on June 29, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. All nominated directors were elected to serve until the 2027 Annual Meeting. Crowe LLP was ratified as the company's independent registered public accounting firm for fiscal 2026. The company’s executive compensation was approved on an advisory (non‑binding) "say‑on‑pay" vote.

Key Details

• Director elections: All listed nominees were elected to serve until the 2027 annual meeting. Examples of vote totals include:
  • Frank L. Jaksch, Jr.: 44,531,507 For / 759,870 Withheld (13,274,979 broker non‑votes reported on director votes)
  • Steven Rubin: 28,495,147 For / 16,796,230 Withheld (notably large withheld total)
  • Hamed Shahbazi: 30,544,086 For / 14,747,291 Withheld
• Auditor ratification (Proposal 2): Crowe LLP ratified — For 56,152,066; Against 2,256,090; Abstain 158,200 (no broker non‑votes).
• Advisory say‑on‑pay (Proposal 3): For 43,188,958; Against 1,930,441; Abstain 171,978; Broker non‑votes 13,274,979.
• The report was signed by Ozan Pamir, Chief Financial Officer, dated June 29, 2026.

Why It Matters
These results confirm the board line‑up and the choice of external auditor for fiscal 2026—both are material governance items for investors. The advisory approval of executive compensation was supported by a majority of votes cast, though a sizable number of broker non‑votes (13.27M) appeared on director and say‑on‑pay items. Several directors received substantial withheld votes (e.g., Rubin and Shahbazi), which investors and governance observers may track as an indicator of shareholder sentiment.